A novel liver cancer therapy targeting tumour stroma

一种针对肿瘤基质的新型肝癌疗法

• 批准号: nhmrc : 1113842
• 负责人: Prof Geoffrey Mccaughan
• 金额: $ 26.42万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-liver-cancer-tumour-stroma/663283
• 关键词: novel; liver; cancer; therapy; targeting

In Australia, there are 1,300 new cases of liver cancer each year with an average survival of 7 months. Liver cancer is now the most rapidly increasing cancer, probably caused by more hepatitis, obesity and diabetes. Our commercial partner has a novel innovative new antibody that shrinks other cancer types and we want to see how well it combats liver cancer in mice. This antibody has a raft of superior features and we have a clear plan towards making it available to patients.

在澳大利亚，每年有1,300例新的肝癌病例，平均生存期为7个月。肝癌现在是增长最快的癌症，可能是由更多的肝炎，肥胖和糖尿病引起的。我们的商业合作伙伴有一种新颖的创新抗体，可以缩小其他癌症类型，我们想看看它在小鼠中对抗肝癌的效果如何。这种抗体具有大量的上级功能，我们有一个明确的计划，使其提供给患者。